BCTX net incomeQ4 2026-$12.32M
BCTX net income was -$12.32M in fiscal Q4 2026 (ended Jul 31, 2026), compared with -$8.09M a year earlier. For the full fiscal 2026 it was -$34.90M, compared with -$26.31M in fiscal 2025.
BriaCell Therapeutics Corp. (BCTX) financials
For fiscal 2026 (ended Jul 31, 2026), BriaCell Therapeutics Corp. reported -$34.90M of net income.
- Net income, FY2026
- -$34.90M
- Free cash flow, FY2026
- -$28.78M
- EPS, diluted, FY2026
- -$6.97
- Cash
- $9.85M
- Market cap
- $34.4M
FY2019FY2026
FY2024FY2026
BCTX revenue and earnings growth
BCTX EPSFY2026-$6.97
BCTX diluted EPS was -$6.97 for fiscal 2026 (ended Jul 31, 2026).
BCTX free cash flowQ4 2026-$5.96M
BCTX free cash flow was -$5.96M in fiscal Q4 2026 (ended Jul 31, 2026). For the full fiscal 2026 it was -$28.78M.
Income statement
| Line item | Jul 31, 2026 | Jul 31, 2025 | Jul 31, 2024 | Jul 31, 2023 | Jul 31, 2022 | Jul 31, 2021 | Jul 31, 2020 | Jul 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $3.1K | - | - |
| Research and development | $29.24M | $21.27M | $27.18M | $15.34M | $8.02M | $2.02M | $2.43M | - |
| Selling, general and admin | $6.82M | $5.93M | $6.15M | $7.94M | $7.27M | $4.96M | $1.51M | - |
| Operating income | -$36.05M | -$27.20M | -$33.33M | -$23.27M | -$15.29M | -$6.98M | -$3.94M | - |
| Interest expense | $29.6K | $37.0K | - | - | $979 | $78.6K | $29.5K | - |
| Pre-tax income | $35.33M | $26.56M | $4.93M | $20.30M | -$26.84M | -$13.82M | - | - |
| Net income | -$34.90M | -$26.31M | -$4.79M | -$20.30M | -$26.84M | -$13.82M | -$4.02M | -$4.71M |
| EPS, basic | -$6.97 | -$62.19 | -$436.80 | -$195.00 | -$259.50 | -$459.00 | - | - |
| EPS, diluted | -$6.97 | -$62.19 | -$436.80 | -$195.00 | -$259.50 | - | - | - |
| Diluted shares | 5.0M | 423,114 | 10,969.9 | 104,131.173 | 103,293.94 | 30,130.527 | 4,759.26 | - |
Balance sheet
| Line item | Jul 31, 2026 | Jul 31, 2025 | Jul 31, 2024 | Jul 31, 2023 | Jul 31, 2022 | Jul 31, 2021 | Jul 31, 2020 | Jul 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.85M | $10.49M | $862.1K | $21.25M | $41.04M | $57.27M | $21.2K | $157.0K |
| Short-term investments | $10.69M | $7.37M | - | - | - | - | - | - |
| Receivables | - | - | - | $18.9K | $24.1K | $12.6K | $22.5K | $2.8K |
| Current assets | $22.04M | $19.93M | $3.65M | $26.95M | $42.35M | $57.80M | $261.5K | $168.5K |
| Total assets | $23.58M | $21.65M | $5.87M | $27.16M | $42.58M | $58.04M | $522.3K | $444.7K |
| Current liabilities | $7.98M | $3.98M | $7.46M | $1.80M | $941.1K | $556.8K | $3.96M | $1.13M |
| Total liabilities | $8.02M | $4.32M | $8.56M | $30.94M | $32.25M | $782.2K | $4.12M | $1.13M |
| Shareholders' equity | $15.56M | $17.33M | -$2.68M | -$3.78M | $10.33M | $27.67M | -$2.74M | -$688.7K |
Cash flow
| Line item | Jul 31, 2026 | Jul 31, 2025 | Jul 31, 2024 | Jul 31, 2023 | Jul 31, 2022 | Jul 31, 2021 | Jul 31, 2020 | Jul 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.65M | -$28.17M | -$24.13M | -$23.74M | -$12.48M | -$7.75M | -$1.27M | - |
| Capital expenditures | $127.0K | - | $456.8K | - | - | - | - | - |
| Free cash flow | -$28.78M | - | -$24.58M | - | - | - | - | - |
| Investing cash flow | -$3.81M | -$7.65M | -$681.8K | - | - | - | - | - |
| Financing cash flow | $31.81M | $45.45M | $4.42M | $3.95M | -$3.74M | $65.00M | $1.17M | - |
| Stock-based compensation | $1.13M | $656.8K | $1.80M | $2.19M | $3.07M | $1.97M | $1.7K | - |
| Depreciation and amortization | - | - | - | - | $15.3K | $15.3K | - | - |
Key ratios
| Line item | Jul 31, 2026 | Jul 31, 2025 | Jul 31, 2024 | Jul 31, 2023 | Jul 31, 2022 | Jul 31, 2021 | Jul 31, 2020 | Jul 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | - | - | - | - | - | -221531.8% | - | - |
| Net margin | - | - | - | - | - | -438748.8% | - | - |
| Return on equity | -224.3% | -151.8% | - | - | -259.8% | -49.9% | - | - |
| Return on assets | -148.0% | -121.5% | -81.6% | -74.7% | -63.0% | -23.8% | -770.5% | -1059.9% |
| Current ratio | 2.76 | 5.01 | 0.49 | 14.96 | 45.00 | 103.81 | 0.07 | 0.15 |
Income statement
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $10.53M | $5.97M | $6.05M | $6.68M | $7.11M | $4.81M | $5.68M | $3.67M | $4.41M | $7.66M | $8.26M | $6.86M |
| Selling, general and admin | $2.05M | $1.65M | $1.48M | $1.64M | $1.44M | $1.52M | $1.48M | $1.49M | $1.36M | $1.57M | $1.57M | $1.65M |
| Operating income | -$12.58M | -$7.62M | -$7.53M | -$8.32M | -$8.55M | -$6.33M | -$7.17M | -$5.15M | -$5.77M | -$9.23M | -$9.83M | -$8.50M |
| Interest expense | $0 | $29.6K | - | - | $0 | $37.0K | - | - | - | - | - | - |
| Net income | -$12.32M | -$7.16M | -$7.22M | -$8.20M | -$8.09M | -$6.13M | -$6.29M | -$5.80M | -$1.21M | $1.72M | -$11.29M | $6.00M |
| EPS, basic | - | -$0.99 | -$2.58 | -$43.50 | - | -$16.42 | -$23.31 | -$326.70 | - | $16.10 | -$106.40 | $57.00 |
| EPS, diluted | - | -$0.99 | -$2.58 | -$43.50 | - | -$16.42 | -$23.31 | -$326.70 | - | $16.10 | -$106.40 | -$75.00 |
| Diluted shares | - | 7.3M | 2.8M | 188,390.6 | - | 373,067 | 269,957 | 17,760.6 | - | 106,544.8 | 106,544.8 | 111,165.94 |
Balance sheet
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.85M | $6.88M | $29.90M | $2.71M | $10.49M | $12.46M | $5.01M | $5.79M | $862.1K | $935.7K | $6.24M | $13.65M |
| Short-term investments | $10.69M | $15.92M | - | $7.46M | $7.37M | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | $15.2K | $30.1K | $21.4K |
| Current assets | $22.04M | $25.39M | $32.18M | $11.35M | $19.93M | $14.79M | $7.16M | $8.22M | $3.65M | $5.53M | $11.74M | $18.41M |
| Total assets | $23.58M | $27.07M | $33.59M | $13.08M | $21.65M | $17.00M | $9.36M | $10.41M | $5.87M | $6.20M | $12.23M | $18.62M |
| Current liabilities | $7.98M | $3.59M | $3.19M | $3.32M | $3.98M | $4.33M | $5.23M | $4.99M | $7.46M | $6.76M | $3.92M | $1.05M |
| Total liabilities | $8.02M | $3.66M | $3.38M | $3.72M | $4.32M | $5.06M | $6.14M | $6.70M | $8.56M | $12.44M | $20.55M | $16.10M |
| Shareholders' equity | $15.56M | $23.41M | $30.21M | $9.35M | $17.33M | $11.94M | $3.23M | $3.71M | -$2.68M | -$6.23M | -$8.32M | $2.52M |
Cash flow
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.96M | -$7.02M | -$7.97M | -$7.70M | -$8.13M | -$7.16M | -$5.92M | -$6.96M | -$4.04M | -$5.08M | -$7.40M | -$7.61M |
| Capital expenditures | $0 | - | - | - | - | - | - | - | - | - | - | - |
| Free cash flow | -$5.96M | - | - | - | - | - | - | - | - | - | - | - |
| Investing cash flow | $4.99M | -$16.00M | $7.28M | -$75.0K | -$7.39M | -$105.0K | -$75.0K | -$75.0K | -$456.8K | - | - | - |
| Financing cash flow | $3.94M | $0 | - | - | $13.56M | $14.71M | $5.22M | $11.96M | - | - | - | - |
| Stock-based compensation | $117.5K | $432.2K | $285.9K | $294.7K | -$120.0K | $224.8K | $285.1K | $267.0K | $377.9K | $392.2K | $500.2K | $533.8K |
| Depreciation and amortization | - | - | - | - | - | $26.7K | - | - | - | $3.8K | $3.8K | $3.8K |
Key ratios
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.76 | 7.07 | 10.10 | 3.42 | 5.01 | 3.41 | 1.37 | 1.65 | 0.49 | 0.82 | 2.99 | 17.59 |
Source: XBRL data BriaCell Therapeutics Corp. files with the SEC, latest filing dated Oct 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Mar 12, 2025; 1-for-10, first reported Mar 10, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
BCTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BCTX | - | - | -$34.90M | - | $34.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
BCTX FAQ
6 questionsIs BCTX profitable?
No. BriaCell Therapeutics Corp. reported a net loss of $34.90M for fiscal 2026 (ended Jul 31, 2026).How much cash and debt does BCTX have?
BriaCell Therapeutics Corp. reported $9.85M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is BCTX free cash flow?
BriaCell Therapeutics Corp. generated -$28.78M of free cash flow for fiscal 2026 (ended Jul 31, 2026), which is operating cash flow of -$28.65M less capital expenditures.What is BCTX earnings per share?
Diluted earnings per share were -$6.97 for fiscal 2026 (ended Jul 31, 2026), from SEC filings, restated for any stock split those filings show.When did BCTX last report financial results?
The latest statements here come from BriaCell Therapeutics Corp.'s 10-K filed on Oct 28, 2026, covering the period ended Jul 31, 2026.Where does this BCTX financial data come from?
Quantisnow builds these statements from the structured XBRL data BriaCell Therapeutics Corp. files with the SEC. It is provided for information only and is not investment advice.